Member Info for Fadec92

Is that code for something trill if so the big cow meet in a busy pub!

So GSK snapped up Tesaro with the PARP inhibitor Niraparib which is Sierra Oncology pairing with a supply deal with Jannsen with our Chk1 phase 1b/2 combination trial!

Can’t understand with the comments of “we are not so good” as this PARP Inhibitor that is on the market and can be acquired in the US and is proven, but increasing data that Chk1 does also a job for a different mechanism in stopping or tumor reduction and for better survival times, that’s why they have partnered with Niraparib with data with synergy!

https://www.tesarobio.com/en/pipeline/niraparib

http://investor.sierraoncology.com/2018-02-27-Sierra-Oncology-and-Janssen-Sign-Supply-Agreement-for-Prostate-Cancer-Study

https://www.halliburton.com/content/dam/ps/public/pinnacle/contents/Papers_and_Articles/web/Diagnostics-Reveal-Stimulation-Effects-AOGR-July-2018.pdf

No misleading on my part and have said in the post a few things we talked about and shame on you to think that, you remind me of the programs where people are slick with their tongue and con people out of money to meet their own ends, someone to stay away from like the colors of a dangerous insect praying on the week!

Shame on you too think that and let me remind you of a poster who come over here and made allegations about what you done to someone over on Reds and I can dig that post out too for everyone can see how embroiled you are, and I’m sure that would definitely be deleted straight away by admin!

D14 you’ve said this all before on many occasions and keep on moving the goalposts to suit, also even the company has said in a public RNS that they are funded, you are only here to disrupt and cause harm to other investors and get a kick out of it, can’t you see that it is a sad thing to do?

On 3 Parker could have organized the take up of the last placing by investors instead of the usual feeding into market!

We demonstrate that inhibition of Chk1 by SRA737 treatment results in micronuclei formation and an induction of STING and Type I interferon signaling, leading to expression of immune cell-recruiting chemokines in cell culture as well as in the tumors of an immune competent murine model of SCLC.

? SRA737 induces PD-L1 expression in SCLC cells in vitro as well as in the tumors isolated from SRA737-treated animals.

? SRA737 inhibits tumor growth and synergizes with an immune checkpoint blockade agent, anti-PD-L1 antibody, to induce tumor regression in an anti-PD-L1 refractory SCLC model.

? This promising combination strategy warrants clinical investigation in SCLC and other cancer types that are refractory to immunotherapy.

http://filecache.investorroom.com/mr5ircnw_sierra/213/download/Sierra_AACR%20Miami%202018_SRA737%20IO_FINAL.pdf

It does happen just got to be patient enough, I know what your thinking “been here forever” 2 years 10 months for me, so are new compared to a lot here so a lot of respect for peeps that have and are holding for the endgame, which is my plan too, in what form that is I don’t know, but it looks as if everything is going the right way!

Theses updates are not going to raise the SP, but give investors confidence that they have invested in a company that has created small molecules that do a job and well if continue with good data, your in the wrong share for temporary gains, although the company structure of late is a big sign including the latest updates from Tim!

The Chk1 so versatile another additional trial coming!

"These encouraging preclinical results highlight an additional potential application for SRA737 that warrants further evaluation beyond our current clinical development programs for the drug as a monotherapy and in combination with replication stress-inducing low dose gemcitabine."

“said Dr. Lauren Byers, Associate Professor at the University of Texas MD Anderson Cancer Center, Houston, Texas. "Remarkably, the combination of SRA737 with an anti-PD-L1 immune checkpoint inhibitor induced tumor regression in this model, providing strong rationale for combining these agents to treat this immunotherapy refractory indication."

“demonstrated significant anti-tumor activity in an immunocompetent preclinical model of small cell lung cancer (SCLC)”

I don’t know if testing has been completed at the Separation plant, how much Argon/Helium is needed to conclude the test for end user satisfaction!

There are wells drilled in area for the logs, lots like Barret 1-14B, but it’s production wells that is needed, after leases acquired then it moves to development of area, guess we’ll have an update explaining the plan with the gases and overall, could be an investor into the project as well as an end user, we will see!

With a lot of wells there on the section you would think that DT would be used on a horizontal well, it’s the data from it that would be of great use, maybe to compare with Halliburton’s refrack tech as they already refrack the Arapahoe extension!

I think if more wells are drilled then it could be on the same terms or possibly a negotiation of all party’s, everyone to gain from this it’s about who gets what percentage!

Would have thought that discussion would have taken place between True and Renegade for there to be a chance to drill more wells, also the development plans would need to go in front of the cogcc and True to decide with Renegade after 8 wells in production!

With Highlands agreement with ConocoPhillips for outer section and Renegades inner sections there must be an agreement with True that we don’t know the details!

MW75 the 8 wells will be producing soon for cash flow, the Kansas project with the selling of the gases to market will be next he was very careful not to give information away so have no details, the acreage that was acquired is in the sweet spots of the reservoir, I asked for more info on plans but as he said there is other wells in area and this is the main focus and assured me that this is very exciting and will let us know what’s going on, but at this point cannot!

The new person VP of engineering Brian Weaver will be taking DT forward as he has the right skills to do so after working with Liberty and Pinnacle where he drove the sales of the company’s technology and now Halliburton’s use the services don’t know how is connected will have to research that, but with his background and his reputation to take forward, also big into analysis of data, worked with Schlumberger and Halliburton’s!

There is a chance of drilling more wells in east Denver, True will look at the production rates of current wells and decide to take forward with Renegade, DM is currently working at the site managing operations for True Oil and the frack operations are going well and completed on schedule!

Not going to be around till after 9am though as family commitments take president!